Some additional info in regards to the Q&A from the 23rd with Brian;
"I can't elaborate further on Item 5.
In 2016, apart from the FDA application, you should expect more hospitals participating in our clinical studies as well as the commencement of a new Adult study. Further clinical study results including diagnosis of additional diseases.
Licensing agreements are also on the cards. Lots to look forward too. In respect to the FDA, should approval be granted, the benefit is both validation and recognition. This will greatly enhance our commercial and trade sale opportunities."
GLTA and good weekend.
Mick
RAP Price at posting:
7.8¢ Sentiment: Buy Disclosure: Held
